Cargando…

Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates

Non-Alcoholic fatty liver disease (NAFLD) is characterized by accumulation of triglycerides (TG) in hepatocytes, which may also trigger cirrhosis. The mechanisms of NAFLD are not fully understood, but insulin resistance has been proposed as a key determinant. AIMS: To determine the TG content and lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamath, Subhash, Chavez, Alberto O., Gastaldelli, Amalia, Casiraghi, Francesca, Halff, Glenn A., Abrahamian, Gregory A., Davalli, Alberto M., Bastarrachea, Raul A., Comuzzie, Anthony G., Guardado-Mendoza, Rodolfo, Jimenez-Ceja, Lilia M., Mattern, Vicki, Paez, Ana Maria, Ricotti, Andrea, Tejero, Mary E., Higgins, Paul B., Rodriguez-Sanchez, Iram Pablo, Tripathy, Devjit, DeFronzo, Ralph A., Dick, Edward J., Cline, Gary W., Folli, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220682/ https://www.ncbi.nlm.nih.gov/pubmed/22125617 http://dx.doi.org/10.1371/journal.pone.0027617

Ejemplares similares

Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons
por: Chavez, Alberto O, et al.
Publicado: (2009)

IMPACT OF OBESITY SEVERITY AND DURATION ON PANCREATIC β-AND α-CELLS DYNAMICS IN NORMOGLYCEMIC NON-HUMAN PRIMATES
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2012)

Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
por: Mehta, Rucha J., et al.
Publicado: (2019)

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
por: Chavez, Alberto O., et al.
Publicado: (2009)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

Energy Expenditure Evaluation in Humans and Non-Human Primates by SenseWear Armband. Validation of Energy Expenditure Evaluation by SenseWear Armband by Direct Comparison with Indirect Calorimetry
por: Casiraghi, Francesca, et al.
Publicado: (2013)

The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
por: Palavicini, Juan P., et al.
Publicado: (2021)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
por: Salehi, Marzieh, et al.
Publicado: (2022)

PSUN299 GLP-1 Contribution to Insulin Secretory Response to Protein Ingestion and Insulin Kinetics Following Gastric Bypass and Sleeve Gastrectomy
por: Rayas, Maria, et al.
Publicado: (2022)

201 Effects of GLP-1 on Glucose and Islet-Cell Secretory Responses to Protein Ingestion After Gastric Bypass or Sleeve Gastrectomy
por: Rayas, Maria S., et al.
Publicado: (2022)

Chronic Reduction of Plasma Free Fatty Acid Improves Mitochondrial Function and Whole-Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals
por: Daniele, Giuseppe, et al.
Publicado: (2014)

Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance
por: Shannon, Chris, et al.
Publicado: (2018)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
por: Gaggini, Melania, et al.
Publicado: (2013)

Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
por: Tripathy, Devjit, et al.
Publicado: (2014)

Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2013)

Eight week exposure to a high sugar high fat diet results in adiposity gain and alterations in metabolic biomarkers in baboons (Papio hamadryas sp.)
por: Higgins, Paul B, et al.
Publicado: (2010)

DSCR9 gene simultaneous expression in placental, testicular and renal tissues from baboon (papio hamadryas)
por: Rodriguez-Sanchez, Irám Pablo, et al.
Publicado: (2012)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

A novel experimental model for human mixed acinar–ductal pancreatic cancer
por: Doiron, Bruno, et al.
Publicado: (2018)

Hyperglycemic Challenge and Distribution of Adipose Tissue in Obese Baboons
por: Kulkarni, Tanmay, et al.
Publicado: (2014)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Actos Now for the prevention of diabetes (ACT NOW) study
por: DeFronzo, Ralph A, et al.
Publicado: (2009)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice
por: Doiron, Bruno, et al.
Publicado: (2016)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2013)

Response to Letter to the Editor from Roy et al: “Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function”
por: Chen, Xi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c67ire0jldrojmhfd9djfcfifu